How Choosing the Right Printer Helps Small Businesses and Content Creators to Save Time, Maximise Productivity and Achieve GrowthRead more Eritrea: World Breastfeeding WeekRead more Eritrean community festival in Scandinavian countriesRead more IOM: Uptick in Migrants Heading Home as World Rebounds from COVID-19Read more Network International & Infobip to offer WhatsApp for Business Banking Services to Financial Institution Clients across AfricaRead more Ambassador Jacobson Visits Gondar in the Amhara Region to Show Continued U.S. Support for the Humanitarian and Development Needs of EthiopiansRead more Voluntary Repatriation of Refugees from Angola to DR Congo ResumesRead more Senegal and Mauritania Are Rich in Resources, Poor in Infrastructure, Now Is the Time to Change That Read more Madinat Jumeirah: Dubai’s Stunning Four Hotel Beach Resort Offers Unirvalled Benefits for Summer StaycationsRead more Measles: EU Provides €450,000 in Humanitarian Response to Measles Outbreaks in SomaliaRead more

GSK spin-off to create consumer healthcare giant

show caption
The spin-off of GSK's consumer healthcare unit, renamed Haleon, is the pharmaceutical company's biggest move in two decades./AFP
Print Friendly and PDF

Jul 18, 2022 - 12:51 PM

LONDON, UNITED KINGDOM — British drugs giant GlaxoSmithKline on Monday demerges its newly-named consumer healthcare unit Haleon, resulting in what is set to be London’s largest new stock market listing in more than a decade.

The new company — owning brands including Sensodyne toothpaste, pain relief drug Panadol and cold treatment Theraflu — is set for a valuation of about £40 billion ($47.4 billion) when it begins trading on the London stock market, according to Bloomberg.

The major strategy shift by GSK chief executive Emma Walmsley comes after she has faced intense activist shareholder pressure over the company’s delays in producing Covid jabs and treatments.

‘Landmark London listing 

“This will be the largest London stock market listing in a decade, with the new company becoming a big beast with a new skin in the consumer goods world,” said Susannah Streeter, senior investment and markets analyst at Hargreaves Lansdown.

It is set to be the capital’s biggest listing since Swiss mining giant Glencore was valued at £38 billion on entry in 2011.

GSK, which owns 68 percent of Haleon, plans to retain six percent of the group following the spin-off.

US pharmaceutical titan Pfizer has said it plans to sell its 32-percent minority stake.

Walmsley, who had led the consumer unit prior to her promotion as head of GSK in 2017, has described the demerger as the group’s most significant corporate change in 20 years.

The split sees GSK “parcelling off a considerable quantity of its sizeable debt pile into Haleon, expected to be around £10 billion”, Streeter said.

Haleon could join London’s top-tier FTSE 100 depending on its market valuation.

Walmsley, part of a group of less than 10 women chief executives running companies on the benchmark index, sees more long-term value in the demerger than a sale.

GSK at the start of the year rejected a £50 billion bid for the unit from consumer goods titan Unilever.

Vaccine push

Alongside the demerger, GSK is expanding further into the field of vaccines, having in May snapped up US biopharmaceutical firm Affinivax for up to $3.3 billion.

Also this year, the British company spent $1.9 billion on US group Sierra Oncology, a specialist in medicines for rare forms of cancer.

Keith Bowman, analyst at Interactive Investor, said the demerger was aimed at giving GSK “increased management focus to each respective business”.

This was the case “particularly for its pharma business which has underperformed rivals such as (Covid vaccine-maker) AstraZeneca over recent years”, he told AFP.

GSK is set to receive £7 billion in dividends at separation.

The consumer healthcare division, whose portfolio of products includes also Centrum multivitamins and anti-inflammatory Voltaren, generates annual sales of about £10 billion.

Haleon will be headquartered in Weybridge, southwest of London.

“The idea is that a more focused consumer business will help boost sales,” said Streeter.

“There will be no change at the top… which is a vote of confidence in Brian McNamara, a former Procter & Gamble executive who has led the division for eight years.”

LMBCBUSINESS.COM uses both Facebook and Disqus comment systems to make it easier for you to contribute. We encourage all readers to share their views on our articles and blog posts. All comments should be relevant to the topic. By posting, you agree to our Privacy Policy. We are committed to maintaining a lively but civil forum for discussion, so we ask you to avoid personal attacks, name-calling, foul language or other inappropriate behavior. Please keep your comments relevant and respectful. By leaving the ‘Post to Facebook’ box selected – when using Facebook comment system – your comment will be published to your Facebook profile in addition to the space below. If you encounter a comment that is abusive, click the “X” in the upper right corner of the Facebook comment box to report spam or abuse. You can also email us.